Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Neuroendocrine Tumor Drug Market Research Report 2019-2025

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Neuroendocrine Tumor Drug Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Neuroendocrine Tumor Drug Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Type
    • 1.4.2 mTOR protein inhibitors
    • 1.4.3 Tyrosine kinase 3 inhibitors
    • 1.4.4 Somatostatin receptor antagonists
    • 1.4.5 Growth hormone releasing factor antagonists
    • 1.4.6 Somatostatin receptor agonists
    • 1.4.7 Others
  • 1.5 Market by Application
    • 1.5.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Application
    • 1.5.2 Hospital
    • 1.5.3 Clinic
    • 1.5.4 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Neuroendocrine Tumor Drug Market Size, Estimates and Forecasts
    • 2.1.1 Global Neuroendocrine Tumor Drug Revenue 2015-2026
    • 2.1.2 Global Neuroendocrine Tumor Drug Sales 2015-2026
  • 2.2 Global Neuroendocrine Tumor Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    • 2.2.1 Global Neuroendocrine Tumor Drug Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Neuroendocrine Tumor Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Neuroendocrine Tumor Drug Competitor Landscape by Players

  • 3.1 Neuroendocrine Tumor Drug Sales by Manufacturers
    • 3.1.1 Neuroendocrine Tumor Drug Sales by Manufacturers (2015-2020)
    • 3.1.2 Neuroendocrine Tumor Drug Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Neuroendocrine Tumor Drug Revenue by Manufacturers
    • 3.2.1 Neuroendocrine Tumor Drug Revenue by Manufacturers (2015-2020)
    • 3.2.2 Neuroendocrine Tumor Drug Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Neuroendocrine Tumor Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Neuroendocrine Tumor Drug Revenue in 2019
    • 3.2.5 Global Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Neuroendocrine Tumor Drug Price by Manufacturers
  • 3.4 Neuroendocrine Tumor Drug Manufacturing Base Distribution, Product Types
    • 3.4.1 Neuroendocrine Tumor Drug Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Neuroendocrine Tumor Drug Product Type
    • 3.4.3 Date of International Manufacturers Enter into Neuroendocrine Tumor Drug Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Neuroendocrine Tumor Drug Market Size by Type (2015-2020)
    • 4.1.1 Global Neuroendocrine Tumor Drug Sales by Type (2015-2020)
    • 4.1.2 Global Neuroendocrine Tumor Drug Revenue by Type (2015-2020)
    • 4.1.3 Neuroendocrine Tumor Drug Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Neuroendocrine Tumor Drug Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Neuroendocrine Tumor Drug Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Type (2021-2026)
    • 4.2.3 Neuroendocrine Tumor Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Neuroendocrine Tumor Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Neuroendocrine Tumor Drug Market Size by Application (2015-2020)
    • 5.1.1 Global Neuroendocrine Tumor Drug Sales by Application (2015-2020)
    • 5.1.2 Global Neuroendocrine Tumor Drug Revenue by Application (2015-2020)
    • 5.1.3 Neuroendocrine Tumor Drug Price by Application (2015-2020)
  • 5.2 Neuroendocrine Tumor Drug Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Neuroendocrine Tumor Drug Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Neuroendocrine Tumor Drug Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Neuroendocrine Tumor Drug by Country
    • 6.1.1 North America Neuroendocrine Tumor Drug Sales by Country
    • 6.1.2 North America Neuroendocrine Tumor Drug Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Neuroendocrine Tumor Drug Market Facts & Figures by Type
  • 6.3 North America Neuroendocrine Tumor Drug Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Neuroendocrine Tumor Drug by Country
    • 7.1.1 Europe Neuroendocrine Tumor Drug Sales by Country
    • 7.1.2 Europe Neuroendocrine Tumor Drug Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Neuroendocrine Tumor Drug Market Facts & Figures by Type
  • 7.3 Europe Neuroendocrine Tumor Drug Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Neuroendocrine Tumor Drug by Region
    • 8.1.1 Asia Pacific Neuroendocrine Tumor Drug Sales by Region
    • 8.1.2 Asia Pacific Neuroendocrine Tumor Drug Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Neuroendocrine Tumor Drug Market Facts & Figures by Type
  • 8.3 Asia Pacific Neuroendocrine Tumor Drug Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Neuroendocrine Tumor Drug by Country
    • 9.1.1 Latin America Neuroendocrine Tumor Drug Sales by Country
    • 9.1.2 Latin America Neuroendocrine Tumor Drug Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Neuroendocrine Tumor Drug Market Facts & Figures by Type
  • 9.3 Central & South America Neuroendocrine Tumor Drug Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Neuroendocrine Tumor Drug by Country
    • 10.1.1 Middle East and Africa Neuroendocrine Tumor Drug Sales by Country
    • 10.1.2 Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Neuroendocrine Tumor Drug Market Facts & Figures by Type
  • 10.3 Middle East and Africa Neuroendocrine Tumor Drug Market Facts & Figures by Application

11 Company Profiles

  • 11.1 Eisai
    • 11.1.1 Eisai Corporation Information
    • 11.1.2 Eisai Description and Business Overview
    • 11.1.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Eisai Neuroendocrine Tumor Drug Products Offered
    • 11.1.5 Eisai Related Developments
  • 11.2 Exelixis, Inc.
    • 11.2.1 Exelixis, Inc. Corporation Information
    • 11.2.2 Exelixis, Inc. Description and Business Overview
    • 11.2.3 Exelixis, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 Exelixis, Inc. Neuroendocrine Tumor Drug Products Offered
    • 11.2.5 Exelixis, Inc. Related Developments
  • 11.3 Foresee Pharmaceuticals, LLC
    • 11.3.1 Foresee Pharmaceuticals, LLC Corporation Information
    • 11.3.2 Foresee Pharmaceuticals, LLC Description and Business Overview
    • 11.3.3 Foresee Pharmaceuticals, LLC Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Products Offered
    • 11.3.5 Foresee Pharmaceuticals, LLC Related Developments
  • 11.4 Hutchison MediPharma Limited
    • 11.4.1 Hutchison MediPharma Limited Corporation Information
    • 11.4.2 Hutchison MediPharma Limited Description and Business Overview
    • 11.4.3 Hutchison MediPharma Limited Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Products Offered
    • 11.4.5 Hutchison MediPharma Limited Related Developments
  • 11.5 Intezyne, Inc
    • 11.5.1 Intezyne, Inc Corporation Information
    • 11.5.2 Intezyne, Inc Description and Business Overview
    • 11.5.3 Intezyne, Inc Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Intezyne, Inc Neuroendocrine Tumor Drug Products Offered
    • 11.5.5 Intezyne, Inc Related Developments
  • 11.6 INVENT Pharmaceuticals, Inc.
    • 11.6.1 INVENT Pharmaceuticals, Inc. Corporation Information
    • 11.6.2 INVENT Pharmaceuticals, Inc. Description and Business Overview
    • 11.6.3 INVENT Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Products Offered
    • 11.6.5 INVENT Pharmaceuticals, Inc. Related Developments
  • 11.7 Ipsen S.A.
    • 11.7.1 Ipsen S.A. Corporation Information
    • 11.7.2 Ipsen S.A. Description and Business Overview
    • 11.7.3 Ipsen S.A. Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 Ipsen S.A. Neuroendocrine Tumor Drug Products Offered
    • 11.7.5 Ipsen S.A. Related Developments
  • 11.8 Jiangsu Hengrui Medicine Co., Ltd.
    • 11.8.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
    • 11.8.2 Jiangsu Hengrui Medicine Co., Ltd. Description and Business Overview
    • 11.8.3 Jiangsu Hengrui Medicine Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Products Offered
    • 11.8.5 Jiangsu Hengrui Medicine Co., Ltd. Related Developments
  • 11.9 Karyopharm Therapeutics, Inc.
    • 11.9.1 Karyopharm Therapeutics, Inc. Corporation Information
    • 11.9.2 Karyopharm Therapeutics, Inc. Description and Business Overview
    • 11.9.3 Karyopharm Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Products Offered
    • 11.9.5 Karyopharm Therapeutics, Inc. Related Developments
  • 11.10 Lexicon Pharmaceuticals, Inc.
    • 11.10.1 Lexicon Pharmaceuticals, Inc. Corporation Information
    • 11.10.2 Lexicon Pharmaceuticals, Inc. Description and Business Overview
    • 11.10.3 Lexicon Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Products Offered
    • 11.10.5 Lexicon Pharmaceuticals, Inc. Related Developments
  • 11.1 Eisai
    • 11.1.1 Eisai Corporation Information
    • 11.1.2 Eisai Description and Business Overview
    • 11.1.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Eisai Neuroendocrine Tumor Drug Products Offered
    • 11.1.5 Eisai Related Developments
  • 11.12 Millennium Pharmaceuticals, Inc.
    • 11.12.1 Millennium Pharmaceuticals, Inc. Corporation Information
    • 11.12.2 Millennium Pharmaceuticals, Inc. Description and Business Overview
    • 11.12.3 Millennium Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 Millennium Pharmaceuticals, Inc. Products Offered
    • 11.12.5 Millennium Pharmaceuticals, Inc. Related Developments
  • 11.13 MolMed S.p.A.
    • 11.13.1 MolMed S.p.A. Corporation Information
    • 11.13.2 MolMed S.p.A. Description and Business Overview
    • 11.13.3 MolMed S.p.A. Sales, Revenue and Gross Margin (2015-2020)
    • 11.13.4 MolMed S.p.A. Products Offered
    • 11.13.5 MolMed S.p.A. Related Developments
  • 11.14 Northwest Biotherapeutics, Inc.
    • 11.14.1 Northwest Biotherapeutics, Inc. Corporation Information
    • 11.14.2 Northwest Biotherapeutics, Inc. Description and Business Overview
    • 11.14.3 Northwest Biotherapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.14.4 Northwest Biotherapeutics, Inc. Products Offered
    • 11.14.5 Northwest Biotherapeutics, Inc. Related Developments
  • 11.15 Novartis AG
    • 11.15.1 Novartis AG Corporation Information
    • 11.15.2 Novartis AG Description and Business Overview
    • 11.15.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
    • 11.15.4 Novartis AG Products Offered
    • 11.15.5 Novartis AG Related Developments
  • 11.16 OctreoPharm Sciences GmbH
    • 11.16.1 OctreoPharm Sciences GmbH Corporation Information
    • 11.16.2 OctreoPharm Sciences GmbH Description and Business Overview
    • 11.16.3 OctreoPharm Sciences GmbH Sales, Revenue and Gross Margin (2015-2020)
    • 11.16.4 OctreoPharm Sciences GmbH Products Offered
    • 11.16.5 OctreoPharm Sciences GmbH Related Developments
  • 11.17 OXiGENE, Inc.
    • 11.17.1 OXiGENE, Inc. Corporation Information
    • 11.17.2 OXiGENE, Inc. Description and Business Overview
    • 11.17.3 OXiGENE, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.17.4 OXiGENE, Inc. Products Offered
    • 11.17.5 OXiGENE, Inc. Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Neuroendocrine Tumor Drug Market Estimates and Projections by Region
    • 12.1.1 Global Neuroendocrine Tumor Drug Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Regions 2021-2026
  • 12.2 North America Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
    • 12.2.1 North America: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
    • 12.2.2 North America: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
    • 12.2.3 North America: Neuroendocrine Tumor Drug Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
    • 12.3.2 Europe: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Neuroendocrine Tumor Drug Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Neuroendocrine Tumor Drug Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Neuroendocrine Tumor Drug Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Neuroendocrine Tumor Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter's Five Forces Analysis
  • 13.5 Primary Interviews with Key Neuroendocrine Tumor Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Neuroendocrine Tumor Drug Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Neuroendocrine Tumor Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neuroendocrine Tumor Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

    Segment by Type, the Neuroendocrine Tumor Drug market is segmented into
    mTOR protein inhibitors
    Tyrosine kinase 3 inhibitors
    Somatostatin receptor antagonists
    Growth hormone releasing factor antagonists
    Somatostatin receptor agonists
    Others

    Segment by Application, the Neuroendocrine Tumor Drug market is segmented into
    Hospital
    Clinic
    Others

    Regional and Country-level Analysis
    The Neuroendocrine Tumor Drug market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Neuroendocrine Tumor Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
    Competitive Landscape and Neuroendocrine Tumor Drug Market Share Analysis
    Neuroendocrine Tumor Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Neuroendocrine Tumor Drug business, the date to enter into the Neuroendocrine Tumor Drug market, Neuroendocrine Tumor Drug product introduction, recent developments, etc.

    The major vendors covered:
    Eisai
    Exelixis, Inc.
    Foresee Pharmaceuticals, LLC
    Hutchison MediPharma Limited
    Intezyne, Inc
    INVENT Pharmaceuticals, Inc.
    Ipsen S.A.
    Jiangsu Hengrui Medicine Co., Ltd.
    Karyopharm Therapeutics, Inc.
    Lexicon Pharmaceuticals, Inc.
    Midatech Pharma Plc .
    Millennium Pharmaceuticals, Inc.
    MolMed S.p.A.
    Northwest Biotherapeutics, Inc.
    Novartis AG
    OctreoPharm Sciences GmbH
    OXiGENE, Inc.

    Buy now